Canagliflozin
Last Updated: 02/24/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 2228 publications
Drug Development.
Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association
Published: December 26, 2025
NRF2-Mediated Anti-Ferroptotic Pathways in Diabetic Cardiomyopathy: Mechanistic Insights, Therapeutic Advances, and Challenges in Cardiovascular Protection.
Journal: Current problems in cardiology
Published: December 12, 2025
Correction to "An SGLT2 inhibitor, canagliflozin, reduces blood glucose level in the renal capillaries and protects the capillary network in the diabetic rats".
Journal: Diabetes, obesity & metabolism
Published: December 09, 2025
Effects of SGLT2 Inhibitors on Clinical Outcomes, Symptoms, Functional Capacity, and Cardiac Remodeling in Heart Failure: A Comprehensive Systematic Review and Multidomain Meta-Analysis of Randomized Trials.
Journal: Journal of clinical medicine
Published: December 05, 2025
Clinical pharmacokinetics on canagliflozin: a systematic review of in-vitro and in-vivo studies.
Journal: Expert review of clinical pharmacology
Published: November 28, 2025
Correction: The SGLT2 Inhibitor Canagliflozin Reduces Atherosclerosis by Enhancing Macrophage Autophagy.
Journal: Journal of cardiovascular translational research
Published: November 28, 2025
Canagliflozin Promotes Structural and Functional Changes in Proximal Tubular Cell Mitochondria of Hypertensive-Diabetic Mice.
Journal: International journal of molecular sciences
Published: November 19, 2025
Noninsulin drugs for type 2 diabetes.
Journal: The Medical letter on drugs and therapeutics
Published: November 19, 2025
Comparison chart: Sodium-glucose cotransporter 2 (SGLT2) inhibitors.
Journal: The Medical letter on drugs and therapeutics
Published: November 19, 2025
Last Updated: 02/24/2026